A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. [electronic resource]
Producer: 20100707Description: 20 p. digitalISSN:- 1479-5876
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Estramustine -- therapeutic use
- Humans
- Interferons -- therapeutic use
- Isotretinoin -- therapeutic use
- Male
- Middle Aged
- Mitoxantrone -- therapeutic use
- Neoplasm Metastasis
- Paclitaxel -- therapeutic use
- Prostatic Neoplasms -- drug therapy
- Proto-Oncogene Proteins c-bcl-2 -- metabolism
- Quality of Life
- Survival Rate
- Teratogens
- Treatment Outcome
- Vinblastine -- analogs & derivatives
- Vinorelbine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.